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Abstract For understanding the mechanism(s) relating inflam-
mation to corticosteroid action, the effect of tumour necrosis
factor-K (TNF-K) on 11L-hydroxysteroid dehydrogenase type 2
(11L-HSD2), the enzyme regulating access of 11L-hydroxycor-
ticosteroids to receptors, was studied in LLC-PK1 cells. We
observed (i) NAD-dependent enzyme activity and mRNA for
11L-HSD2, but not 11L-HSD1, (ii) increasing 11L-HSD2
activity with increasing degree of differentiation and (iii) a
concentration-dependent down-regulation by TNF-K, phorbol
myristate acetate (PMA) or glucose of activity and mRNA of
11L-HSD2. The decrease of activity and mRNA by glucose and
PMA, but not that by TNF-K, was abrogated by the protein
kinase C inhibitor GF-109203X. The effect of TNF-K on 11L-
HSD2 was reversed by inhibiting the mitogen-activated protein
kinases ERK with PD-098050 and p38 by SB-202190, or by
activating protein kinase A with forskolin. Overexpression of
MEK1, an ERK activator, down-regulated the 11L-HSD2
activity. In conclusion, TNF-K decreases 11L-HSD2 activity
and thereby enhances glucocorticoid access to glucocorticoid
receptors to modulate the inflammatory response. ß 2001 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
During in£ammation, glucocorticoids appear in higher
extracellular concentrations, suggesting a modulating role in
the stress response [1^3]. Two pro-in£ammatory cytokines,
tumour necrosis factor-K (TNF-K) and interleukin-1L, often
exert synergistic e¡ects, and have been shown to link in£am-
mation with corticosteroid production by enhancing the secre-
tion of corticotropin-releasing factor and thereby ultimately
elevating corticosterone levels [2,3]. Intracellular glucocorti-
coid concentrations in target organs depend not only on the
extracellular steroid concentrations, but in addition on the
intracellular availability of these steroid hormones [1,4,5].
The intracellular access of steroids to receptors is regulated
by the enzymes 11L-hydroxysteroid dehydrogenase types 1
and 2 (11L-HSD1 and 11L-HSD2), which interconvert biolog-
ically active 11L-hydroxysteroids and their inactive 11-keto
congeners (reviewed in [6]).
Our group recently showed that TNF-K increases the ex-
pression and reductase activity of the [NADP(H)]-dependent
enzyme 11L-HSD1 in non-endocrine cells [4]. As a conse-
quence, 11-ketosteroids with low a⁄nity for glucocorticoid
receptors (GR) were converted into 11L-hydroxycorticoste-
roids, with high a⁄nity for GR, and their biological activity
was shown by inhibition of group II phospholipase A2 [4].
Thus, during in£ammation, not only the hypothalamo^pitui-
tary^adrenal axis is activated but, in addition, peripheral pro-
duction of corticosteroids occurs by activation of 11L-HSD1.
11L-HSD2 requires NAD as a cofactor and shows predom-
inantly oxidative activity by converting active 11L-hydroxy-
into inactive 11-ketosteroids [6]. The 11L-HSD2 accounts for
the selective access of aldosterone to the mineralocorticoid
receptor (MR) by inactivating cortisol [6]. 11L-HSD2 is thus
highly expressed in mineralocorticoid target tissues such as the
renal cortical collecting duct and colon [6,7]. Absence or in-
hibition of 11L-HSD2 results in inappropriate access of glu-
cocorticoids to epithelial MR with distal tubular sodium re-
tention and increased blood pressure [8,9].
In the present investigation we focussed on the e¡ect of
TNF-K on 11L-HSD2 and found that TNF-K decreases the
expression and activity of 11L-HSD2, an e¡ect mediated by
mitogen-activated protein (MAP) kinases and reversed by ac-
tivating protein kinase A (PKA).
2. Materials and methods
2.1. Materials
Corticosterone, dehydrocorticosterone, glycyrrhetinic acid (GA)
and phorbol 12-myristate 13-acetate (PMA) were from Sigma and
NAD(H), NADP(H), deoxynucleotides, RNase inhibitor and avian
myeloblastosis virus reverse transcriptase (AMV RT) from Roche
Diagnostics. [1,2,6,7-3H]Corticosterone (87 Ci/mmol) and [K-32P]-
dCTP (V3000 Ci/mmol) were purchased from Amersham. Bicincho-
ninic acid protein assay kits were from Pierce. Thin layer chromatog-
raphy plates (SIL G-25 UV254) were from Macherey-Nagel (Oensin-
gen, Switzerland). PD-98059, SB-202190, FTase inhibitor III and
forskolin were from Calbiochem. Bisindolylmaleimide I hydrochloride
salt (GF-109203X, abbreviated GFX) was from Alexis (San Diego,
CA, USA) and Taq-Gold DNA polymerase from Perkin Elmer Cetus.
2.2. Cell cultures
LLC-PK1 cells (porcine renal epithelial cells with characteristics of
proximal and distal convoluted tubules) were maintained in Dulbec-
co’s modi¢ed Eagle’s medium (DMEM) with 0.45% glucose, 10%
foetal calf serum (FCS), penicillin (100 U/ml) and streptomycin (100
Wg/ml) [10]. For experiments cells were seeded at a density of 100 000
cells per well in 24-well culture plates (Becton Dickinson, Basel, Swit-
zerland) or 400 000 cells per well in 6-well culture plates. Cells were
stimulated after reaching con£uence when abundant domes appeared,
in the absence of serum. At the same time PD-098059 (50 WM), SB-
202190 (10 WM), GFX (2 WM), PMA (100 nM), forskolin (10 WM)
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were added to the cultures for 24^48 h. The e¡ect of TNF-K (Pharma
Biotechnology, Hannover, Germany) on the viability of LLC-PK1
cells was assessed by light microscopy, trypan blue dye exclusion,
and release of lactate dehydrogenase (LDH) at the end of the incu-
bations. Values for LDH release in the supernatant were calculated as
percentage of total LDH release after freezing and thawing the re-
spective cells.
2.3. Transient and stable overexpression of MEK1
pGEM-MEK (Ser218Asp; Ser222Asp) is a pGEM-7Zf(3) vector
(Promega, Zurich, Switzerland) carrying a mouse MEK1 gene mu-
tated at positions 218 and 222 from serine to aspartate (a gift from
R.L. Erikson, Cambridge, MA, USA). This doubly mutated form of
MEK1 has a four-fold higher ability to activate ERK1 compared to
the wild-type form in intact cells [11]. For expression in LLC-PK1
cells, the Asp718-NheI fragment from pGEM-MEK was subcloned
into the Asp718-XbaI site of pcDNA3 (Invitrogen, Leek, The Nether-
lands) in the sense and antisense orientations. LLC-PK1 cells were
transfected with these pcDNA3-MEK1 plasmids or with the empty
vector. Activity of stable clones was measured 2 days after reaching
con£uence in situ and total protein was determined as given below.
For transient transfections 130 000 LLC-PK1 cells were seeded into a
12-well plate. Cells were transfected the following day with 0.5 Wg
total DNA and 3 Wl Fugene 6 (Roche Diagnostics, Basel, Switzerland)
in a volume of 1 ml growth medium. Activity of 11L-HSD2 was
assessed 48 h after transfection.
2.4. Reporter gene assay
We engineered LLC-PK1 cells to carry the bacterial L-galactosidase
gene (lacZ) under the control of the mouse mammary tumour virus
(MMTV) promoter using a similar strategy as previously described by
Satoh et al. [12]. The MMTV promoter contains essential glucocorti-
coid response elements. Thus the stably transfected LLC-PK1 cell line
expresses L-galactosidase when exposed to 11L-hydroxysteroids. For
the assessment of the transactivation, LLC-PK1 cells transfected with
MMTV-lacZ were incubated after di¡erentiation with 1 nM TNF-K
with or without PD-098059 or the corresponding control solutions for
48 h. Thereafter the medium was replaced by charcoal-stripped
DMEM (1 g/l glucose, 10% FCS) together with varying concentra-
tions of corticosterone. After an additional 48 h the cells were sub-
jected to the in situ L-galactosidase assay as described [12].
2.5. 11L-HSD type 1 and type 2 activity in whole cells and homogenates
11L-HSD2 activity was assessed by the conversion of corticosterone
to 11-dehydrocorticosterone using medium with 5 nCi
[3H]corticosterone and 10 nM corticosterone at 37‡C for 30 min
and reductase activity using medium with 5 nCi [3H]11-dehydrocorti-
costerone and 500 nM 11-dehydrocorticosterone [4]. 400 WM cofactor
(NAD, NADH, NADPH) was added to homogenates only [10].
2.6. Reverse transcription and PCR
Total RNA was extracted from LLC-PK1 cells following the gua-
nidinium thiocyanate method. Concentration was determined by mea-
suring the absorption at 260 nm and integrity was checked by loading
1 Wg on a 1% formaldehyde agarose gel. 1 Wg of each sample RNA
was reverse transcribed into cDNAs using 1 U AMV RT and 10 pmol
random hexamer primers according to the manufacturer’s protocol.
Polymerase chain reaction was essentially performed as described
previously [4]. Primers for 11L-HSD2 were: forward primer, 5P-
TGCTGCAGATGGACCTGACCAA and reverse primer, 5P-TAG-
TAGTGGATGAAGTACATGAGC. These PCR primers were origi-
nally designed by Leckie et al. [10] to regions of 11L-HSD2 cDNA,
which are conserved between the four species for which sequences of
11L-HSD2 were available (human, rat, rabbit, and sheep); these se-
quences are not found in other short-chain alcohol dehydrogenases.
Primers for pig GAPDH (GenBank accession number U48832) were:
forward primer, position 112^133 of the corresponding cDNA and
reverse primer, position 685^704 of the corresponding cDNA.
2.7. Western blot analysis
Total protein (50 Wg) was loaded on a denaturing 10% polyacryl-
amide gel. Prestained protein standards (Boehringer Mannheim) were
used as markers. Electrophoresis and blotting on polyvinylidene £uo-
ride membranes (Immobilon-P, Millipore, Bedford, MA, USA) were
performed as described in [4]. Detection of doubly phosphorylated
ERK with a monoclonal antibody (New England Biolabs, Beverly,
MA, USA) was performed according to the manufacturer’s instruc-
tions. Detection was performed with the ECL Plus chemolumines-
cence detection kit (Amersham).
2.8. Analysis of data
Data are means ( þ S.D.). Statistical comparisons were performed
using Welch t-test for independent means or ANOVA.
3. Results
3.1. Regulation of 11L-HSD2 activity by TNF-K, PMA and
glucose
In LLC-PK1 cells the oxidation of corticosterone to dehy-
drocorticosterone was determined in both cell lysates and
whole cells. GA, a known inhibitor of 11L-HSD activity, re-
duced oxidative activity at 10 WM in whole cells and in cell
extracts by more than 95% (P6 0.001, n = 14) [4,6]. Conver-
sion of dehydrocorticosterone to corticosterone was measured
in cell lysates and whole cells with 10 nM or 500 nM dehy-
drocorticosterone. No 11-oxoreductase activity was observed.
Addition of 0.2% Triton X-100, an agent inhibiting 11L-
HSD2 but not 11L-HSD1 activity [7], completely abolished
conversion of corticosterone to dehydrocorticosterone.
To exclude competitive inhibition of 11L-HSD2 activity by
TNF-K, glucose or PMA we tested similar concentrations of
these substances in lysates of LLC-PK1 cells ; none decreased
11L-HSD2 activity.
The activity of 11L-HSD2 in LLC-PK1 cells increased with
increasing con£uence and di¡erentiation (P6 0.0001, Fig. 1).
Addition of TNF-K (1 nM) down-regulated the activity of
11L-HSD2 in con£uent cells (P = 0.046, Fig. 1) in media
with or without serum. We checked three clones of LLC-
Fig. 1. E¡ect of con£uence and TNF-K on 11L-HSD2 activity in
LLC-PK1 cells. The activity of 11L-HSD2 increased signi¢cantly
with increasing con£uence of cells with or without TNF-K. Data are
given from a single study, repeated twice, performed in triplicate
(mean þ S.D.).
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PK1 cells for 11L-HSD2 activity and found a range from 2 to
30 pmol/h/mg protein. In all clones TNF-K and PMA de-
creased the activity by about 50% after 48 h. For all subse-
quent experiments the clone with an activity of 8 þ 2 pmol/h/
mg protein was used.
TNF-K down-regulated the activity of 11L-HSD2 dose-de-
pendently (Fig. 2). This e¡ect was not due to cell death, be-
cause after 48 h (i) more than 95% of cells were alive and
(ii) an average of 15% (n = 18) increase of total protein was
observed, re£ecting proliferation of LLC-PK1 cells [13]. For
all subsequent experiments 1 nM of TNF-K was used.
Because 11L-HSD2 activity is di¡erentiation-dependent, we
tested whether activation of protein kinase C (PKC) a¡ects
11L-HSD2 activity. PMA and glucose, two known PKC acti-
vators, decreased the activity of 11L-HSD2 by about 50%
(P6 0.0001, Fig. 3). The e¡ect of PMA and glucose but not
of TNF-K was reversed with the PKC inhibitor GFX
(P = 0.0005, Fig. 3A) [14,15]. TNF-K (P6 0.0001), PMA
(P = 0.002) and high glucose (P = 0.009) decreased the 11L-
HSD2 mRNA level in parallel with the activity of this enzyme
(Fig. 3B). This e¡ect was reversed by GFX only when the cells
were incubated with PMA (P6 0.0005) or high glucose
(P = 0.0148).
3.2. Role of MAP kinases in the regulation of 11L-HSD2
Because TNF-K is known to induce phosphorylation of
ERK, a fact also observed in LLC-PK1 cells 24 and 48 h after
stimulation (Fig. 4A) the signal transduction pathway acti-
vated by TNF-K was explored. For this purpose we used
the MAP kinase ERK inhibitor PD-098059, the MAP kinase
p38 inhibitor SB-202190 [16,17] and the PKA activator for-
skolin. When con£uent LLC-PK1 cells were incubated with
PD-098059 (50 WM), the activity of 11L-HSD2 increased
(P6 0.001, Fig. 4); similar but less pronounced e¡ects were
seen with SB-202190 (10 WM) and forskolin (10 WM)
(P6 0.002). The inhibitory e¡ect of TNF-K on 11L-HSD2
was partly reversed by these inhibitors (P = 0.01) and forsko-
lin (P = 0.0003) (Fig. 4). Down-regulation of 11L-HSD2 by
TNF-K was reversed with 50 WM of the ERK inhibitor PD-
098059 (data not shown). In line with these inhibition studies
transient overexpression of MEK1 reduced the activity of
11L-HSD2 (P = 0.007) (Fig. 5). In addition to the transient
overexpression studies three di¡erent stably transfected clones
overexpressing MEK1 were analysed. The basal activities of
11L-HSD2 of MEK1-expressing clones in relation to their
corresponding MEK1 antisense-expressing cells ( = 100%)
were 53.5 þ 20.6% (range 29.8^67.7% with a median of
63.1%). There was no di¡erence between antisense- and empty
vector-transfected cells in terms of 11L-HSD2 activity.
Fig. 2. Inhibition of 11L-HSD2 activity by TNF-K in LLC-PK1
cells. Numbers as in Fig. 1.
Fig. 3. Impact of TNF-K, PMA and high glucose concentrations
with or without the PKC inhibitor GFX on the activity (A) and
mRNA level (B) of 11L-HSD2 in LLC-PK1 cells. TNF-K, PMA or
high glucose concentrations reduced mRNA and activity of 11L-
HSD2. GFX abrogated the inhibitory e¡ect of PMA and high glu-
cose on mRNA (A) and on 11L-HSD2 activity (B) but not of TNF-
K. Numbers as in Fig. 1.
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3.3. TNF-K down-regulates activity of 11L-HSD2 and increases
the biological e¡ect of glucocorticoids
To clarify whether the down-regulated activity of 11L-
HSD2 by TNF-K increases the biological e¡ect of glucocorti-
coids we engineered LLC-PK1 cells with a stably inserted bac-
terial L-galactosidase gene controlled by the MMTV promoter
which contains several steroid response elements. This cell line
therefore expresses L-galactosidase only when active glucocor-
ticoids are present. Indeed, TNF-K enhanced the 11L-hydrox-
ysteroid corticosterone e¡ect, an e¡ect reversed by inhibiting
ERK with PD-098059 (Fig. 6). When GA was added together
with corticosterone the steroid action was increased, indicat-
ing an important role of 11L-HSD2 in modulating steroid-
induced gene expression.
4. Discussion
Con£uent LLC-PK1 cells di¡erentiate [18]. Therefore we
analysed the activity of 11L-HSD2 as a function of the con-
£uence stage and showed that increasing con£uence increased
the 11L-HSD2 activity (Fig. 1). A comparable stage and dif-
ferentiation dependence has been reported for the Na/glu-
cose cotransporter, the formation of tight junctions, the trans-
epithelial salt or water transport and brush border enzymes in
LLC-PK1 cells [18,19]. This present observation of di¡erentia-
tion-dependent 11L-HSD2 induction in vitro is relevant for
understanding in vivo situations. Several groups have ob-
served complex developmental patterns in vivo for activityFig. 4. A: Western blot of cell extracts of phosphorylated ERK (42
and 44 kDa) of LLC-PK1 cells stably transfected with MEK1. Cells
were incubated without or with 1 nM TNF-K for 24 and 48 h. 50
Wg was loaded per lane. B: E¡ect of inhibition of the MAP kinases
ERK by PD-098059 and p38 by SB-202190 and of the activation of
PKA by forskolin in LLC-PK1 cells in the presence and absence of
TNF-K. The mean ( þ S.D.) of two independent experiments per-
formed in triplicate is given.
Fig. 5. Transient overexpression of MEK1 decreases 11L-HSD2 ac-
tivity. In each well 0.5 Wg of total DNA was transfected. The rela-
tive amount of pcDNA3-MEK1 plasmid increases from left to right
resulting in a dose-dependent decrease of 11L-HSD2 activity. The
results from a single study performed in triplicate are given; the ex-
periment was repeated twice with the same results.
Fig. 6. In£uence of TNF-K with and without inhibition of ERK by
PD-098059 (PD) on glucocorticoid-dependent gene expression of
L-galactosidase. Addition of TNF-K increased corticosterone-induced
L-galactosidase activity. Inhibition of ERK by PD-098059 reversed
this e¡ect. Inhibition of 11L-HSD2 with GA (10 WM) elevated the
steroid-induced L-galactosidase activity. Numbers as in Fig. 5.
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and/or 11L-HSD1 mRNA levels and/or 11L-HSD2 mRNA
levels in foetal or early postnatal tissue [20,21]. Down-regula-
tion of 11L-HSD2 means that the corresponding cells are ex-
posed to increased intracellular concentrations of 11L-hydrox-
ysteroids, and up-regulation of 11L-HSD2 has the opposite
e¡ect. Thus each individual cell regulates the exposure to glu-
cocorticosteroids di¡erentially according to its developmental
stage.
At least two di¡erent signal transduction pathways are in-
volved in the regulation of 11L-HSD2 (Fig. 7). One pathway
involves activation of PKC and MAP kinases, the second the
activation of MAP kinases by a PKC-independent pathway.
Previous studies have shown that TNF-K and PKC cause
downstream activation of MAP kinases [22,23] ; three lines
of evidence in the present investigation support the relevance
of PKC in the regulation of 11L-HSD2 activity. First, the
inverse relationship between the activity of PKC and 11L-
HSD2 during cellular growth is indirect and correlative evi-
dence; PKC activity is high during cellular growth and low at
con£uence when the cell cycle is arrested [18] ; in contrast, the
activity of 11L-HSD2 is low during growth and high at con-
£uence, when LLC-PK1 cells di¡erentiate and stop cycling
(Fig. 1). Secondly, PMA reduces the activity of 11L-HSD2,
an e¡ect abrogated by the PKC inhibitor GFX (Fig. 3).
Third, high glucose concentrations diminish the activity of
11L-HSD2 in LLC-PK1 cells ; high glucose concentrations
are known to exhibit a similar e¡ect on PKC as PMA [14].
The glucose-induced decline in 11L-HSD2 activity (Fig. 3) is
in accordance with the reduced 11L-HSD2 observed in rats
treated with streptozotocin [24].
Both MAP kinases ERK and p38 are involved in the TNF-
K-induced reduction of 11L-HSD2 expression. Inhibition of
ERK in con£uent LLC-PK1 cells leads to an increase in
11L-HSD2 activity which may be due to undi¡erentiated, di-
viding cells in culture with active ERK (Fig. 4) [25]. TNF-K
induces proliferation and dedi¡erentiation of LLC-PK1 cells,
an e¡ect paralleled by down-regulation of tissue-speci¢c genes
such as 11L-HSD2 [19]. The observation that LLC-PK1 cells
are responsive to TNF-K, an e¡ect partially reversed by for-
skolin, is in line with the report that the transepithelial resis-
tance response of LLC-PK1 cells to TNF-K can be abrogated
by forskolin [26]. Forskolin enhanced 11L-HSD2 activity, a
¢nding in accordance with the up-regulation of 11L-HSD2 by
forskolin in JEG-3 cells [27], a human choriocarcinoma cell
line. The mechanism of action of forskolin in this model is
open to speculation. Forskolin induces cAMP-dependent
PKA. PKA is an important physiological inhibitor of the
MAP kinase cascade and cell proliferation by inhibiting
Raf-1 [28] and/or by inducing phosphatase activity [29].
Thus, it is conceivable that forskolin reduced the e¡ect of
TNF-K on 11L-HSD2 activity by inhibition of MAP kinase
activation. Alternatively, forskolin might induce other tran-
scription factors, such as CREB.
The biological relevance of enhanced access of glucocorti-
coids to receptors by TNF-K-induced down-regulation of 11L-
HSD2 activity was qualitatively assessed in a reporter gene
assay (Fig. 7), and the e¡ect of TNF-K reversed by inhibiting
the ERK-dependent signal transduction pathway. The inhib-
itory e¡ect of TNF-K on 11L-HSD2 activity was more pro-
nounced in this reporter gene assay than one would predict on
the basis of the relative inhibition of 11L-HSD2 in untrans-
fected LLC-PK1 cells by TNF-K and GA, suggesting that
factors in addition to ligand metabolism may account for
the modulation of the corticosteroid-induced L-galactosidase
expression by TNF-K observed in transfected cells. One pos-
sible explanation is the recently described enhanced transcrip-
tional activity of steroid receptors by TNF-K [30].
Zipser et al. [31] observed low aldosterone despite high
renin levels in septic patients with appropriately elevated plas-
ma cortisol concentrations. The most likely mechanism for
this hyperreninaemic hypoaldosteronism is TNF-K-mediated
inhibition of angiotensin II- and ACTH-induced expression
of aldosterone synthase [32,33]. Thus aldosterone does not
explain the clinically bene¢cial increased renal sodium reten-
tion which is seen as part of the complex haemodynamic
response in septic patients. The present observation, however,
that TNF-K down-regulates transcription and activity of 11L-
HSD2, does. Under normal conditions 11L-HSD2 protects
mineralocorticoid receptors from glucocorticoids. When the
activity of 11L-HSD2 is reduced, as it is in the presence of
TNF-K, glucocorticoids act as mineralocorticoids and enhance
renal sodium retention [6,8,9,34].
In conclusion, TNF-K increases the formation of biologi-
cally active glucocorticoids at the site of action by enhancing
the reductase activity of 11L-HSD1 as previously shown [4],
and by inhibiting the oxidative activity of 11L-HSD2 as dem-
onstrated in the present investigation. This di¡erential regu-
lation of the expression of 11L-HSD 1 [4] and 11L-HSD2 by
TNF-K might contribute not only to overcoming unwanted
e¡ects in in£ammatory stress as discussed recently [4], but also
to enhancing renal sodium retention by inappropriate access
of glucocorticoids to epithelial MR.
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